Synmosa Biopharma (Taiwan) Performance
| 4114 Stock | TWD 33.60 0.10 0.30% |
The entity has a beta of 0.0779, which indicates not very significant fluctuations relative to the market. As returns on the market increase, Synmosa Biopharma's returns are expected to increase less than the market. However, during the bear market, the loss of holding Synmosa Biopharma is expected to be smaller as well. At this point, Synmosa Biopharma has a negative expected return of -0.19%. Please make sure to validate Synmosa Biopharma's standard deviation, total risk alpha, maximum drawdown, as well as the relationship between the jensen alpha and treynor ratio , to decide if Synmosa Biopharma performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Synmosa Biopharma has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest abnormal performance, the Stock's basic indicators remain stable and the latest fuss on Wall Street may also be a sign of long-term gains for the venture sophisticated investors. ...more
| Begin Period Cash Flow | 638.3 M | |
| Total Cashflows From Investing Activities | 83.9 M |
Synmosa |
Synmosa Biopharma Relative Risk vs. Return Landscape
If you would invest 3,795 in Synmosa Biopharma on September 12, 2024 and sell it today you would lose (435.00) from holding Synmosa Biopharma or give up 11.46% of portfolio value over 90 days. Synmosa Biopharma is generating negative expected returns and assumes 0.7325% volatility on return distribution over the 90 days horizon. Simply put, 6% of stocks are less volatile than Synmosa, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Synmosa Biopharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Synmosa Biopharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Synmosa Biopharma, and traders can use it to determine the average amount a Synmosa Biopharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.2599
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | 4114 |
Estimated Market Risk
| 0.73 actual daily | 6 94% of assets are more volatile |
Expected Return
| -0.19 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.26 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Synmosa Biopharma is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Synmosa Biopharma by adding Synmosa Biopharma to a well-diversified portfolio.
Synmosa Biopharma Fundamentals Growth
Synmosa Stock prices reflect investors' perceptions of the future prospects and financial health of Synmosa Biopharma, and Synmosa Biopharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Synmosa Stock performance.
| Return On Equity | 0.0894 | |||
| Return On Asset | 0.0223 | |||
| Profit Margin | 0.18 % | |||
| Operating Margin | 0.09 % | |||
| Current Valuation | 17.93 B | |||
| Shares Outstanding | 327.14 M | |||
| Price To Earning | 14.65 X | |||
| Price To Book | 3.09 X | |||
| Price To Sales | 4.06 X | |||
| Revenue | 3.23 B | |||
| EBITDA | 507.92 M | |||
| Cash And Equivalents | 1.28 B | |||
| Cash Per Share | 3.96 X | |||
| Total Debt | 2.27 B | |||
| Debt To Equity | 0.50 % | |||
| Book Value Per Share | 15.83 X | |||
| Cash Flow From Operations | 444.29 M | |||
| Earnings Per Share | 2.34 X | |||
| Total Asset | 10.32 B | |||
About Synmosa Biopharma Performance
Evaluating Synmosa Biopharma's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Synmosa Biopharma has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Synmosa Biopharma has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Synmosa Biopharma Corporation, a specialty pharmaceutical company, researches and develops, manufactures, markets, and distributes pharmaceutical and healthcare products under the Synmosa brand name in Taiwan. The company was incorporated in 1980 and is based in Taipei, Taiwan. SYNMOSA BIOPHARMA operates under Drug ManufacturersSpecialty Generic classification in Taiwan and is traded on Taiwan OTC Exchange.Things to note about Synmosa Biopharma performance evaluation
Checking the ongoing alerts about Synmosa Biopharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Synmosa Biopharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Synmosa Biopharma generated a negative expected return over the last 90 days | |
| About 25.0% of the company shares are owned by insiders or employees |
- Analyzing Synmosa Biopharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Synmosa Biopharma's stock is overvalued or undervalued compared to its peers.
- Examining Synmosa Biopharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Synmosa Biopharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Synmosa Biopharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Synmosa Biopharma's stock. These opinions can provide insight into Synmosa Biopharma's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Synmosa Stock Analysis
When running Synmosa Biopharma's price analysis, check to measure Synmosa Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Synmosa Biopharma is operating at the current time. Most of Synmosa Biopharma's value examination focuses on studying past and present price action to predict the probability of Synmosa Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Synmosa Biopharma's price. Additionally, you may evaluate how the addition of Synmosa Biopharma to your portfolios can decrease your overall portfolio volatility.